Oramed soars on successful results with oral insulin capsule in T1DM

Oramed Pharmaceuticals (ORMP) rises 34% in premarket trading.

The company says "patient responses positively correlated with administered doses, as did the duration of the effect," in a study testing the pharmacokinetic dose response of ORMD-0801 in type 1 diabetes.

ORMP will "continue to move forward with this indication" along with studies in type 2 diabetes. (PR)

From other sites
Comments (1)
  • sparkinson
    , contributor
    Comments (64) | Send Message
    Congratulations to you,Orimed !
    27 Dec 2013, 11:24 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs